Suchergebnisse - "Nigro, Olga"

PubPharm (9)

1

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Buti, S. | Bersanelli, M. | Perrone, F. | +58

CommentIn: Eur J Cancer. 2021 Sep;155:313-314. - PMID 34373189

2

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Cortellini, A. | Cannita, K. | Tiseo, M. | +49

CommentIn: Eur J Cancer. 2021 Sep;155:294-295. - PMID 34364743

3

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

enthalten in: Journal for immunotherapy of cancer | 2021

von Cortellini, A. | Di Maio, M. | Nigro, O. | +58

4

Combination of radiation therapy for brain metastasis and anti-PD-1/PD-L1 treatment in non-small cell lung cancer : two cases and review of the literature

enthalten in: Anti-cancer drugs | 2021

von Nigro, O. | Tuzi, A. | Coppola, A. | +3

5

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients : A case-control matched analysis from a large multicenter study

enthalten in: Thoracic cancer | 2021

von Cortellini, A. | De Giglio, A. | Cannita, K. | +48

6

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

enthalten in: Cancer immunology, immunotherapy : CII | 2020

von Cortellini, A. | Tiseo, M. | Banna, G. | +67

7

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

enthalten in: Clinical lung cancer | 2020

von Cortellini, A. | Friedlaender, A. | Banna, G. | +68

8

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50% : a multicenter study with external validation

enthalten in: Journal for immunotherapy of cancer | 2020

von Cortellini, A. | Ricciuti, B. | Tiseo, M. | +47

9

Psoriatic arthritis induced by anti-PD1 and treated with apremilast : a case report and review of the literature

enthalten in: Immunotherapy | 2020

von Nigro, O. | Pinotti, G. | Gueli, R. | +4

1
[1]